These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 1534442)

  • 21. Influence of hypertension on cardiovascular outcomes in hemodialysis patients.
    Birchem JA; Fraley MA; Senkottaiyan N; Alpert MA
    Semin Dial; 2005; 18(5):391-5. PubMed ID: 16191179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac disease in patients with end-stage renal disease.
    Staffeld CG; Pastan SO
    Cardiol Clin; 1995 May; 13(2):209-23. PubMed ID: 7614511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Traditional and non-traditional risk factors as contributors to atherosclerotic cardiovascular disease in end-stage renal disease.
    Yao Q; Pecoits-Filho R; Lindholm B; Stenvinkel P
    Scand J Urol Nephrol; 2004; 38(5):405-16. PubMed ID: 15764253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eccentric Left Ventricular Hypertrophy and Sudden Death in Patients with End-Stage Kidney Disease.
    de Roij van Zuijdewijn CL; Hansildaar R; Bots ML; Blankestijn PJ; van den Dorpel MA; Grooteman MP; Kamp O; ter Wee PM; Nubé MJ
    Am J Nephrol; 2015; 42(2):126-33. PubMed ID: 26382055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A
    J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Epidemiology of cardiovascular disease in CKD-MBD].
    Di Micco L; Mozzillo GR; Cianciaruso B
    G Ital Nefrol; 2009; 26 Suppl 49():S3-10. PubMed ID: 19941272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations of Left Ventricular Hypertrophy and Geometry with Adverse Outcomes in Patients with CKD and Hypertension.
    Paoletti E; De Nicola L; Gabbai FB; Chiodini P; Ravera M; Pieracci L; Marre S; Cassottana P; Lucà S; Vettoretti S; Borrelli S; Conte G; Minutolo R
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):271-9. PubMed ID: 26668021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of hypertension in renal failure patients: when do we overtreat? When do we undertreat?
    Rosansky SJ
    Blood Purif; 1996; 14(4):315-20. PubMed ID: 8873957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypertension and future cardiovascular health in pediatric end-stage renal disease patients.
    Flynn JT
    Blood Purif; 2012; 33(1-3):138-43. PubMed ID: 22269342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of erythropoietin on cardiovascular diseases.
    Sunder-Plassmann G; Hörl WH
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S20-5. PubMed ID: 11576916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A
    Bratisl Lek Listy; 2004; 105(10-11):368-73. PubMed ID: 15658577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular mortality in end-stage renal disease.
    Collins AJ
    Am J Med Sci; 2003 Apr; 325(4):163-7. PubMed ID: 12695721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations.
    Chirakarnjanakorn S; Navaneethan SD; Francis GS; Tang WH
    Int J Cardiol; 2017 Apr; 232():12-23. PubMed ID: 28108129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coronary flow reserve abnormalities in patients with diabetes mellitus who have end-stage renal disease and normal epicardial coronary arteries.
    Ragosta M; Samady H; Isaacs RB; Gimple LW; Sarembock IJ; Powers ER
    Am Heart J; 2004 Jun; 147(6):1017-23. PubMed ID: 15199350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis].
    Kes P; Reiner Z; Brunetta B
    Lijec Vjesn; 2002; 124(11-12):372-7. PubMed ID: 12679979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predialysis management and predictors for early mortality in uremic patients who die within one year after initiation of dialysis therapy.
    Biesenbach G; Hubmann R; Janko O; Schmekal B; Eichbauer-Sturm G
    Ren Fail; 2002 Mar; 24(2):197-205. PubMed ID: 12071593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of various antihypertensive agents on cardiovascular risk factors in patients with renal failure.
    Zarama M; Raij L
    Am J Kidney Dis; 1993 May; 21(5 Suppl 2):100-7. PubMed ID: 8494007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypertension and accelerated atherosclerosis in endstage renal disease.
    Huysmans K; Lins RL; Daelemans R; Zachée P; De Broe ME
    J Nephrol; 1998; 11(4):185-95. PubMed ID: 9702869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contributive factors to cardiovascular hypertrophy in renal failure.
    London GM; Marchais SJ; Guerin AP; Métivier F
    Am J Hypertens; 1989 Nov; 2(11 Pt 2):261S-263S. PubMed ID: 2530994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Left ventricular geometry and cardiovascular mortality based on haemodialysis patient autopsy analyses.
    Mimura I; Nishi H; Mise N; Mori M; Sugimoto T
    Nephrology (Carlton); 2010 Aug; 15(5):549-54. PubMed ID: 20649875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.